BioAlberta Renews Call for PMPRB Consultation
On March 7, 2019, BioAlberta, Montreal InVivo and Life Sciences Ontario wrote a letter to Prime Minister Justin Trudeau's office, and two senior ministers responsible for health and innovation policy regarding the Patented Medicine Prices Review Board (PMPRB) regulations.
On April 15, 2019, we received an email response from the Strategic Health Policy Branch of Health Canada.
In follow up to the April correspondence, the tri-province associations replied requesting the PMO and those with broader responsibility to reconsider the proposed PMPRB reform, and thereby stand up for governance and evidence-based policy-making, access to medicines and our innovative life sciences sector.